The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: An open-label, non-randomized, phase IV study.
 
Wenwen Zhang
No Relationships to Disclose
 
Shichun Lu
No Relationships to Disclose
 
Bingyang Hu
No Relationships to Disclose
 
Tao Wan
No Relationships to Disclose
 
Hongguang Wang
No Relationships to Disclose
 
Jun Han
No Relationships to Disclose
 
Ze Zhang
No Relationships to Disclose
 
Junning Cao
No Relationships to Disclose
 
Xianlei Xin
No Relationships to Disclose
 
Yingwei Pan
No Relationships to Disclose
 
Minggen HU
No Relationships to Disclose
 
Mingyi Chen
No Relationships to Disclose
 
Yongliang Chen
No Relationships to Disclose
 
Zhanyu Yang
No Relationships to Disclose
 
Shouwang Cai
No Relationships to Disclose
 
Wenbin Ji
No Relationships to Disclose
 
Chenggang Li
No Relationships to Disclose
 
Shuang Tong
Employment - 3D Medicines
Honoraria - 3D Medicines
Consulting or Advisory Role - 3D Medicines
 
Feilong Zhao
Employment - 3D Medicines
Honoraria - 3D Medicines
Consulting or Advisory Role - 3D Medicines
 
Xiaochen Zhao
Employment - 3D Medicines
Honoraria - 3D Medicines
Consulting or Advisory Role - 3D Medicines